Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CA2 | P00918 | 13/20 | 0.84 |
| ▸ | CA1 | P00915 | 12/20 | 0.84 |
| ▸ | CA9 | Q16790 | 8/20 | 0.74 |
| ▸ | CA12 | O43570 | 4/20 | 0.74 |
| ▸ | KMT2A | Q03164 | 6/20 | 0.68 |
| ▸ | MEN1 | O00255 | 5/20 | 0.68 |
| ▸ | NPSR1 | Q6W5P4 | 2/20 | 0.68 |
| ▸ | PSMD14 | O00487 | 2/20 | 0.68 |
| ▸ | POLB | P06746 | 2/20 | 0.68 |
| ▸ | MAPT | P10636 | 2/20 | 0.68 |
| ▸ | CACNA1B | Q00975 | 2/20 | 0.68 |
| ▸ | APBA1 | Q02410 | 2/20 | 0.68 |
| ▸ | RECQL | P46063 | 1/20 | 0.68 |
| ▸ | CTDSP1 | Q9GZU7 | 1/20 | 0.68 |
| ▸ | SAE1 | Q9UBE0 | 1/20 | 0.68 |
| ▸ | UBA2 | Q9UBT2 | 1/20 | 0.68 |
| ▸ | FGB | P02675 | 1/20 | 0.59 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.59 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.59 |
| ▸ | PLEC | Q15149 | 1/20 | 0.59 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6225517 | 0.84 | CA1 (0.84) | CA2CA1CA9CA12KMT2A | |
| SCHEMBL13980021 | 0.84 | CA1 (0.84) | CA2CA1CA9CA12KMT2A | |
| SCHEMBL8421687 | 0.84 | CA2 (0.84) | CA2CA1CA9CA12KMT2A | |
| SCHEMBL27468719 | 0.84 | CA2 (0.84) | CA2CA1CA9CA12KMT2A | |
| SCHEMBL8422583 | 0.83 | CA2 (1.00) | CA2CA1CA9CA12KMT2A | |
| SCHEMBL8804052 | 0.83 | CA1 (0.81) | CA2CA1CA9CA12KMT2A | |
| SCHEMBL27482936 | 0.83 | CA2 (0.81) | CA2CA1CA9CA12KMT2A | |
| SCHEMBL9449429 | 0.80 | CA2 (0.77) | CA2CA1CA9CA12KMT2A | |
| SCHEMBL20284431 | 0.80 | CA2 (0.77) | CA2CA1CA9CA12KMT2A | |
| SCHEMBL11698866 | 0.80 | CA2 (0.77) | CA2CA1CA9CA12KMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 13 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8362252-B2 | Carbostyril compound | OTSUKA PHARMACEUTICAL CO., LTD. (JP) | 2013-01-29 | — | — | US | disclosed |
| EP-1797082-B1 | CARBOSTYRIL COMPOUND | OTSUKA PHARMA CO LTD (JP) | 2012-08-29 | — | — | EP | disclosed |
| EP-2426128-A1 | Carbostyril compound | Otsuka Pharmaceutical Co., Limited (JP) | 2012-03-07 | — | — | EP | disclosed |
| US-20100261705-A1 | CARBOSTYRIL COMPOUND | OTSUKA PHARMACEUTICAL CO., LTD. | 2010-10-14 | — | — | US | disclosed |
| US-7777038-B2 | Carbostyril compound | OTSUKA PHARMACEUTICAL CO., LTD. (JP) | 2010-08-17 | — | — | US | disclosed |
| US-20090326008-A1 | NF-kappa B Inhibitor | OTSUKA PHARMACEUTICAL CO., LTD. (JP) | 2009-12-31 | — | — | US | disclosed |
| EP-2043644-A1 | NF- B INHIBITOR | Otsuka Pharmaceutical Co., Ltd. (JP) | 2009-04-08 | — | — | EP | disclosed |
| WO-2007119600-A9 | CARBAZOLE COMPOUND | OTSUKA PHARMA CO LTD (JP) | 2008-05-02 | — | — | WO | disclosed |
| WO-2008010601-A1 | NF- ϰB INHIBITOR | OTSUKA PHARMACEUTICAL CO., LTD. (JP) | 2008-01-24 | — | — | WO | disclosed |
| WO-2007119600-A1 | CARBAZOLE COMPOUND | OTSUKA PHARMACEUTICAL CO., LTD. (JP) | 2007-10-25 | — | — | WO | disclosed |
| US-20070179173-A1 | Carbostyril compound | OTSUKA PHARMACEUTICAL CO., LTD. (JP) | 2007-08-02 | — | — | US | disclosed |
| EP-1797082-A1 | CARBOSTYRIL COMPOUND | Otsuka Pharmaceutical Company, Limited (JP) | 2007-06-20 | — | — | EP | disclosed |
| WO-2006035954-A1 | CARBOSTYRIL COMPOUND | OTSUKA PHARMACEUTICAL CO., LTD. (JP) | 2006-04-06 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090326008-A1 | NF-kappa B Inhibitor | NFKBIA, NFKB2, IKBKB | CA2 823/4885CA1 3276/4885CA9 2466/4885 |
| US-20070179173-A1 | Carbostyril compound | GTF2F1, F3, GTF2F2 | CA2 254/4885CA1 2592/4885CA9 895/4885 |
| US-20100261705-A1 | CARBOSTYRIL COMPOUND | GTF2F1, F3, GTF2F2 | CA2 254/4885CA1 2592/4885CA9 895/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.